Israel

Israel has a technically mature psychedelic research ecosystem, but not a general legal medical market for classical psychedelics. The Dangerous Drugs Ordinance remains the backbone of control, with Ministry of Health routes for narcotics, imports, registration, research and exceptional clinical use.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Israel.

1
Israel's clearest present-day access route is supervised esketamine for treatment-resistant depression, not broad classical psychedelic prescribing.
2
Public/HMO evidence supports esketamine coverage under criteria; routine reimbursement for psychiatric IV ketamine is much less clear.
3
MDMA is active in trauma research, including a Sheba-sponsored post-7-October PTSD trial, but historical compassionate use should not be framed as current open access.
4
The strongest research domains are trauma/PTSD, treatment-resistant depression, ketamine/esketamine implementation and neurobiological mechanism work.
5
Greater Tel Aviv and the central corridor are the main operational cluster; Jerusalem is a strong academic and translational node.
6
Company and non-profit claims are useful ecosystem signals but should be checked against registries, journals or public-sector documents before being treated as settled facts.

Research Snapshot

Blossom currently tracks 23 psychedelic clinical trials connected to Israel, including 5 active studies.

Active trials: 5
Total trials: 23
Stakeholders: 14
Events: 3

Top Compounds

Ketamine(9)
MDMA(8)
Esketamine(2)
Psilocybin(1)

Active Trial Preview

View all trials →

Medical Access Snapshot

Israel has documented public/HMO access to intranasal esketamine under criteria, while racemic ketamine is off-label and payer-specific. Classical psychedelics remain controlled, investigational or exceptional-access therapies rather than routine reimbursed medicines.

View trials→View stakeholders→View events→Open access guide→

Regulatory Status

Israel is best described as a controlled-substance jurisdiction with medical and scientific exceptions. The Dangerous Drugs Ordinance remains central, and Ministry of Health routes cover registration, import/export and individual or off-label approvals. Public material supports a real supervised esketamine pathway for treatment-resistant depression, including HMO criteria and Ministry safety material. Racemic ketamine can be used through ordinary clinical and off-label mechanisms, but public evidence for a single national psychiatric reimbursement rule is weaker. Psilocybin, MDMA and other classical psychedelics remain trial, research or exceptional-access matters rather than routinely authorised medicines.

History of Research in Israel

Israel's psychoactive-drug research strength has long coexisted with restrictive drug law. The Dangerous Drugs Ordinance sets the control frame, while Ministry of Health functions determine how controlled substances, imports and exceptional uses can move through authorised scientific or medical channels. # # #

The psychiatric treatment arc moved earlier through ketamine and esketamine than through classical psychedelics. Shalvata's completed ketamine route-comparison study and later real-world esketamine publications show that rapid-acting glutamatergic treatment became clinically meaningful before psilocybin or MDMA did. # #

The 2019 MAPS-reported Ministry approval for MDMA-assisted psychotherapy compassionate use in PTSD is an important historical policy signal. It should be kept in history rather than described as proof of a current open national programme. #

Since 2023 the ecosystem has become more explicit. Tel Aviv University launched its Institute for Integrative Psychedelic Research, Jerusalem-linked groups published psilocybin preclinical work, and post-7-October trauma research pushed PTSD and substance-exposure questions further into mainstream public-health relevance. # # # #

Tel Aviv and Jerusalem

Greater Tel Aviv and the central corridor are the strongest single region to spotlight. The cluster includes Tel Aviv University's psychedelic institute, Sagol neuroscience infrastructure, Sheba in Ramat Gan, and psychiatric-service research nodes such as Shalvata and Lev Hasharon. # # # #

Jerusalem is the strongest secondary node. The Hadassah and Hebrew University orbit is visible through psilocybin preclinical work, translational psychiatry and protocol development. It is a major academic strand rather than a broad patient-access centre. #

The ecosystem also includes non-profits and suppliers, but those claims need careful handling. MAPS Israel is important historically and organisationally, while company supply announcements are useful for mapping activity but do not replace regulator records, registries or peer-reviewed outcomes. # #

Research Focus

The live Israeli pipeline is concentrated in PTSD/trauma, treatment-resistant depression and ketamine/esketamine implementation. Named signals include the Sheba-sponsored group-versus-individual MDMA-assisted therapy trial for PTSD after 7 October 2023, Shalvata ketamine route-comparison work and published real-world esketamine outcomes. # # #

Israel also has a visible translational psilocybin strand. Hebrew University and Hadassah-linked investigators have published preclinical work relevant to OCD-like and tic-related behaviour, while public sources indicate continuing interest in moving this line toward human protocols. That is research activity, not current patient availability. #

Post-7-October trauma has become a major driver. Israeli groups are studying Nova survivors, trauma exposure, recreational drug use and possible short-term psychological associations. These are observational signals and should not be overstated as treatment evidence. # #

Key Milestones

1973

Israel's Dangerous Drugs Ordinance is reissued in modern form and remains the backbone of controlled-substance regulation.

2016

Shalvata begins a ketamine route-comparison study focused on depression treatment applicability.

2019

MAPS reports Ministry approval for a 50-patient MDMA-assisted psychotherapy compassionate-use protocol for PTSD.

2020-2021

Health-system materials show esketamine moving into public and HMO implementation for treatment-resistant depression.

2023

Tel Aviv University inaugurates its Institute for Integrative Psychedelic Research.

2024

Israeli real-world esketamine outcomes are published in Journal of Psychiatric Research.

2024

Israeli groups publish early Nova survivor drug-use and mental-health outcome work.

2024

Hebrew University/Hadassah-linked investigators publish psilocybin preclinical findings relevant to OCD-like behaviour.

2026

ClinicalTrials.gov confirms the Sheba-sponsored MDMA group-versus-individual PTSD trial after the 7 October events.

Future Outlook

In the next 12-24 months, Israel is more likely to produce evidence and operating experience than broad legal liberalisation. The strongest watch areas are PTSD, treatment-resistant depression, ketamine/esketamine implementation, and institutional platforms around Sheba, Tel Aviv University and Hadassah/Hebrew University. # # # #

Regulatory change is likely to be incremental. Israel may see more site openings, import approvals and research procedures for psilocybin or MDMA, but public material reviewed here does not support imminent general authorisation for classical psychedelics as ordinary prescribed medicines. # # #

Reimbursement will probably remain split. Esketamine is the current access anchor, while IV or racemic ketamine is likely to stay provider-, institution- or payer-specific. Classical psychedelics remain a research and exception question until regulators and payers have approved products and delivery models to assess. # # #